Masimo (MASI) Competitors $172.96 +3.84 (+2.27%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MASI vs. LIVN, CNMD, VAR, INMD, BLFS, RMD, IDXX, DXCM, STE, and PODDShould you be buying Masimo stock or one of its competitors? The main competitors of Masimo include LivaNova (LIVN), CONMED (CNMD), Varian Medical Systems (VAR), InMode (INMD), BioLife Solutions (BLFS), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), and Insulet (PODD). These companies are all part of the "medical" sector. Masimo vs. LivaNova CONMED Varian Medical Systems InMode BioLife Solutions ResMed IDEXX Laboratories DexCom STERIS Insulet Masimo (NASDAQ:MASI) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Do institutionals & insiders have more ownership in MASI or LIVN? 86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend MASI or LIVN? Masimo presently has a consensus price target of $167.00, suggesting a potential downside of 3.45%. LivaNova has a consensus price target of $69.17, suggesting a potential upside of 34.78%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe LivaNova is more favorable than Masimo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Masimo 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71LivaNova 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation & earnings, MASI or LIVN? Masimo has higher revenue and earnings than LivaNova. Masimo is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMasimo$2.05B4.52$81.50M$1.45119.28LivaNova$1.24B2.24$17.55M$0.42122.19 Is MASI or LIVN more profitable? Masimo has a net margin of 3.85% compared to LivaNova's net margin of 1.91%. Masimo's return on equity of 14.98% beat LivaNova's return on equity.Company Net Margins Return on Equity Return on Assets Masimo3.85% 14.98% 6.95% LivaNova 1.91%13.81%7.07% Does the MarketBeat Community favor MASI or LIVN? Masimo received 69 more outperform votes than LivaNova when rated by MarketBeat users. However, 69.20% of users gave LivaNova an outperform vote while only 63.89% of users gave Masimo an outperform vote. CompanyUnderperformOutperformMasimoOutperform Votes46063.89% Underperform Votes26036.11% LivaNovaOutperform Votes39169.20% Underperform Votes17430.80% Which has more volatility & risk, MASI or LIVN? Masimo has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Does the media prefer MASI or LIVN? In the previous week, Masimo had 6 more articles in the media than LivaNova. MarketBeat recorded 12 mentions for Masimo and 6 mentions for LivaNova. LivaNova's average media sentiment score of 1.13 beat Masimo's score of 0.88 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Masimo 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMasimo and LivaNova tied by winning 9 of the 18 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Masimo News Delivered to You Automatically Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MASI vs. The Competition Export to ExcelMetricMasimoElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.26B$3.46B$5.38B$8.84BDividend YieldN/A1.70%5.13%4.09%P/E Ratio119.2818.65105.0417.81Price / Sales4.5267.101,233.12158.46Price / Cash28.3647.0340.4136.29Price / Book6.334.047.096.50Net Income$81.50M$89.83M$119.65M$226.22M7 Day Performance7.38%0.51%2.25%4.03%1 Month Performance21.81%6.35%-2.34%4.92%1 Year Performance86.70%21.27%33.97%29.30% Masimo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MASIMasimo4.2479 of 5 stars$172.96+2.3%$167.00-3.4%+86.7%$9.26B$2.05B119.285,200Analyst ForecastLIVNLivaNova4.2267 of 5 stars$51.70+3.3%$69.17+33.8%+16.5%$2.81B$1.15B123.102,900Positive NewsCNMDCONMED4.5862 of 5 stars$71.58+1.3%$79.80+11.5%-30.5%$2.21B$1.24B17.004,000Positive NewsVARVarian Medical SystemsN/A$177.07flatN/AN/A$16.26B$3.17B45.2910,000INMDInMode2.0838 of 5 stars$18.49+1.4%$22.60+22.3%-18.0%$1.55B$492.05M9.99480BLFSBioLife Solutions0.9632 of 5 stars$25.39+1.5%$27.50+8.3%+91.7%$1.18B$143.27M-23.95409Insider TradeAnalyst RevisionRMDResMed4.8188 of 5 stars$243.60+0.8%$225.70-7.3%+59.7%$35.76B$4.69B32.269,980Positive NewsIDXXIDEXX Laboratories4.8723 of 5 stars$419.37+0.2%$552.38+31.7%-12.8%$34.34B$3.66B40.4411,000News CoveragePositive NewsGap DownDXCMDexCom4.9861 of 5 stars$74.48-1.0%$104.59+40.4%-34.3%$29.09B$3.62B44.609,600Insider TradeNews CoveragePositive NewsSTESTERIS4.9927 of 5 stars$215.77+1.7%$253.00+17.3%+5.8%$21.30B$5.14B49.2618,179Ex-DividendPositive NewsHigh Trading VolumePODDInsulet4.4129 of 5 stars$262.99-1.3%$253.27-3.7%+41.1%$18.45B$1.70B45.033,000News CoveragePositive News Related Companies and Tools Related Companies LivaNova Alternatives CONMED Alternatives Varian Medical Systems Alternatives InMode Alternatives BioLife Solutions Alternatives ResMed Alternatives IDEXX Laboratories Alternatives DexCom Alternatives STERIS Alternatives Insulet Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MASI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Masimo Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Masimo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
